You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
SBC: Metselex, Incorporated Topic: 105ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
An Interactive Education Program to Reduce High Risk Behavior in Adolescents
SBC: KLEIN BUENDEL, INC. Topic: NICHDInternet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
SBC: ROCK IMMUNE LLC Topic: 102Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Post-surgical Incision Management Device to Prevent Ostomy Complications
SBC: FISTULA SOLUTION CORPORATION Topic: 102Project Summary/Abstract Over 100,000 patients of all ages undergo ostomy surgery in the United States (US) annually due to a variety of pathophysiologic conditions including colorectal cancer, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), bowel obstruction, diverticulitis, and many other medical conditions. Ostomy surgery may also be necessary in cases of severe abdominal ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDAbstract. Bone marrow is one of the most radiation-sensitive tissues, and patients acutely exposed to total body irradiation (TBI) doses rt 2 Gy develop severe neutropenia, thrombocytopenia, anemia, and lymphopenia within days to weeks of exposure, often dying from infections (due to a lack of neutrophils) and uncontrolled bleeding (insufficient platelets) (referred to as the hematopoietic acute r ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SensiTrak: Automated Assessment of Forelimb Sensation
SBC: VULINTUS, INC Topic: NINDSProject Abstract Current common methods for measuring somatosensory function in preclinical rodent models generally rely on withdrawal responses to uncomfortable or painful stimuli. These tests can be stressful to the animal, while also yielding a high variability in measured responses, and repetitive testing in longitudinal models may even result in chronic pain states. To better understand the c ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
SBC: NEUREXIS THERAPEUTICS, INC. Topic: NINDSProject Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults
SBC: MOAI TECHNOLOGIES, LLC Topic: NIAProject Summary/Abstract Alzheimer’s disease (AD) affects more than six million Americans currently and is projected to affect 14 million at a cost of $1.2 trillion in 2050. Despite its tremendous impacts and the limited influence of pharmacological therapies, attention has been brought to non-pharmacological interventions as promising therapeutic strategies for the prevention of cognitive decli ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients
SBC: Allander Biotechnologies Topic: NIDCRSummary Oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy (RT or CRT) and a limiting factor to using the optimal dose of radiation for effective cancer treatment. Intensity modulated RT (IMRT) and stereotactic Body RT (SBRT) spare more normal tissues and lessen chronic side effects, but not oral mucosa in head and neck cancer patients. To date, Pali ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of novel therapeutics for cancer cachexia
SBC: EMMYON, INC. Topic: NCIPROJECT SUMMARY / ABSTRACT Cancer-induced skeletal muscle atrophy is a central and defining feature of the cancer cachexia syndrome, a highly prevalent condition that affects over 50% of patients with advanced cancer and over 500,000 patients per year in the U.S. In addition to being highly prevalent, cancer-induced skeletal muscle atrophy has devastating consequences for patients; it reduces phys ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health